Benjamin Besse, MD, PhD explores the evolving landscape of Antibody-Drug Conjugates (ADCs), a class of targeted cancer therapy that combines antibodies with chemotherapy drugs. The speaker discusses the three main components of ADCs: the vector (antibody), the target (specific tumor cell markers), and the payload (chemotherapy linked by a chemical bond). Highlighting recent clinical trials, such as the Shion L-01 study, the video delves into the challenges and potential of ADCs in treating lung cancer and the implications of biomarker-driven approaches to enhance therapeutic outcomes. The discussion also touches on future strategies in oncology that might integrate or compare biomarker-based patient selection.